ArticleThe Journal of clinical investigation1996
Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease.
Article in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 58 citations in OpenAlex.
- The Role of APOA-I in Alzheimer's Disease: Bridging Peripheral Tissues and the Central Nervous System.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Association of SNP rs5069 inGenes · 2022Article
- BMP1 5'UTR + 104 T/C gene variation: can be a predictive marker for serum HDL and apoprotein A1 levels in male patients with coronary heart disease.Molecular biology reports · 2018Article
- Apolipoprotein A1 polymorphisms and risk of coronary artery disease: a meta-analysis.Archives of medical science : AMS · 2017Article
- Genetic determinants of clinical heterogeneity of the coronary artery disease in the population of Hyderabad, India.Human genomics · 2017Article
- Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease.Diagnostic pathology · 2015Article
- Article
- Molecular genetics of atherosclerosis.Human genetics · 2009Review
- Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease.Lipids in health and disease · 2008Article
- Synergistic effect between apolipoprotein E and apolipoprotein A1 gene polymorphisms in the risk for coronary artery disease.Molecular and cellular biochemistry · 2008Article
- Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk?Vascular health and risk management · 2008Review
- Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2007Article
- Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function.Naunyn-Schmiedeberg's archives of pharmacology · 2005Article
- Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.Annals of the rheumatic diseases · 2005Article
- Angiotensin-converting enzyme and apolipoproteins genes polymorphism in coronary artery disease.Clinical cardiology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated HDL-cholesterol (C) and apo AI are associated with decreased coronary artery disease (CAD) risk. We determined distributions of two MspI polymorphisms of the apo AI gene, associated in other studies with increased HDL-C, among 644 patients aged < or = 65 years in relation to circulating lipids and CAD severity assessed angiographically. The rare allele distributions at both sites were in Hardy-Weinberg equilibrium in these patients but the base changes were not associated with HDL-C and apo AI levels. However, patients homozygous for the -75 bp substitution were more likely to have one or more significantly diseased vessels (> 50% luminal obstruction)(OR: 4.75, 95%CI: 1.10- 20.46) as also were patients with the rare +83 bp alleles (OR: 2.56, 95%CI: 1.13-5.81). While there was an additive effect of the two polymorphisms to have severe CAD (OR: 6.33, 95%CI: 1.33-30.02), the polymorphism at +83 bp remained significant in predicting CAD severity after adjusting for other variables in a logistic regression analysis (OR: 2.95, 95%CI: 1.26-6.90), which was also strongly associated with the positive family CAD history (P = 0.009). We conclude that patients with these base changes in this Australian coronary population do not have increased HDL-C and apo AI levels but do have more severe CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.